In this webinar, we present Biointron’s proven expertise in two discovery approaches: VHH Phage Display for single-domain antibody generation and AbDrop® Single B Cell Screening for rapid antibody discovery.
Successful antibody discovery requires more than just access to powerful platforms – it demands the experience to apply them efficiently and strategically. Representative case studies are discussed to illustrate how Biointron’s seasoned scientific team overcomes technical hurdles, tackles challenging targets, shortens discovery timelines, and consistently delivers high-quality antibodies, thus offering a reliable path from target to candidate.
Key Topics Include:
- Major antibody discovery approaches overview.
- Introduction of Biointron Phage Display VHH antibody discovery solution and case studies.
- Introduction of Biointron AbDrop antibody discovery solution and case studies.
- Summary & Biointron at a glance.
Presenters
Director of Discovery Services
Biointron
Dr. Gang Liu is Director of Discovery Services at Biointron, and has devoted himself to biological sciences and antibody therapeutics research for more than 20 years. Before joining Biointron, Dr. Liu worked in renowned biotech such as Genscript, and prestigious academic institutions, including Children's Hospital LA, UC Irvine, and City of Hope Medical Center. Dr. Liu earned his Ph.D. degree from Academy of Military Medical Sciences in China, 2007, specializing in cancer research.
Production Partner
Biointron
Founded in 2012 and certified to ISO 9001:2015, Biointron is a CRO specializing in antibody discovery, expression, and optimization services for biotech and pharmaceutical companies. Biointron holds a leading position in the antibody expression service industry. From gene sequence to purified antibodies, our production only takes 2 weeks. We have delivered tens of thousands of recombinant antibodies for more than 3,000 biotech and pharma companies worldwide.
Additional Content From Biointron
Accelerating Antibody Discovery: Integrating Microfluidics, HT Expression, and Early Developability Platform
In this webinar, Dr. Lei Shi introduces Biointron's antibody discovery platform and applications.
Introduction to Bispecific Antibodies and Their Production
In this webinar, Dr. Brady Wu discusses bispecific antibody drugs and their production.
Additional Content From Scientist.com
How to Avoid Expensive Redesign Cycles in Antibody Discovery
Learn how integrated antibody discovery and engineering strategies can accelerate the path from hit to optimized lead in less than 12 months while minimizing costly redesign cycles.
Beyond Exposure: Integrating PK/PD for Translational Predictive Power
Learn to integrate PK/PD modeling and strategic biomarkers to bridge the translational gap. Improve clinical predictability for NCEs, ADCs, and large molecules in this technical webinar.
Advancing the Manufacture of Mesenchymal Stromal Cells and Derived Extracellular Vesicles in Stirred-Tank Bioreactors Through Enhanced Bioprocess Control
Learn how to scale the production of MSCs and extracellular vesicles using bioreactor control and real-time monitoring for more consistent therapies.
Related Content
From Clinical Data to Actionable Assets for Pharmaceutical R&D
In this webinar, learn to transform raw clinical and biobanking data into research-ready assets to accelerate pharmaceutical R&D.
Improving Preclinical Decision-Making in Obesity and CKD with Translational In Vivo Phenotyping
Join us to learn how in-depth in vivo phenotyping using patient-relevant models can improve preclinical decision-making.